<DOC>
	<DOC>NCT02192970</DOC>
	<brief_summary>The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.</brief_summary>
	<brief_title>Bevacizumab Against Recurrent Retinal Detachment</brief_title>
	<detailed_description />
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age â‰¥ 18 years Eyes with rhegmatogenous retinal detachment Presence of PVR Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy. Recent intravitreal injection of an antiVEGF agent less than 3 months prior Secondary retinal detachment repair Use of silicone oil as tamponade agent Patients less than 18 years of age Pregnancy Known allergy or contraindication to intravitreal bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Retinal detachment</keyword>
	<keyword>Proliferative vitreoretinopathy</keyword>
</DOC>